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Abstract 
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of 
cytotoxic treatment. It continues to affect a significant proportion of patients despite 
the widespread use of anti-emetic medication. In traditional medicine, ginger 
(Zingiber officinale) has been used to prevent and treat nausea in many cultures for 
thousands of years. However, its use has not been confirmed in the chemotherapy 
context.  To determine the potential use of ginger as a prophylactic or treatment of 
CINV, a systematic literature review was conducted. Reviewed studies comprised 
randomised controlled trials or cross-over trials that investigated the anti-CINV effect 
of ginger as the sole independent variable in chemotherapy patients. Seven studies 
met the inclusion criteria. All studies were assessed on methodological quality and 
their limitations were identified.  Studies were mixed in their support of ginger as an 
anti-CINV treatment in patients receiving chemotherapy, with three demonstrating a 
positive effect, two in favour but with caveats and two showing no effect on 
measures of CINV. Future studies are required to address the limitations identified 
before clinical use can be recommended.  
Key words: nausea, ginger, chemotherapy, CINV  
Introduction 
Chemotherapy is one of medicine’s key interventions in the treatment of cancer. 
While cytotoxic interventions for cancer are efficacious, they are  often accompanied 
by a variety of adverse effects. Chemotherapy-induced nausea and vomiting (CINV) 
is a relatively common side effect of this treatment.  A combination of different 
classes of anti-emetic medications such as 5-HT3 antagonists, neurokinin 1 (NK1) 
receptor antagonists, corticosteroids and anti-anxiolytics have been shown to have 
additive effects and are commonly prescribed for patients having chemotherapy.  
Vomiting has now been largely controlled but efforts to control nausea have been 
less successful; affecting upwards of 60% of patients.1 Persistent nausea is also 
considered the most distressing symptom for patients in this setting.2,3 This is of 
particular concern in oncology patients as nausea and vomiting can adversely affect 
food intake, increasing the risk of malnutrition during treatment. Previous studies 
report one in two patients in this setting as malnourished.4. The cumulative effect of 
pre-treatment and treatment-related malnutrition can be one of compromised 
immune function, decreased performance status, poor response to treatment, and 
sometimes, treatment discontinuation.5-7  
The use of integrative or complementary therapies has been steadily increasing in 
western countries.8 This wide-spread use of integrative therapies has resulted in an 
increased interest in the investigation of these therapies as either stand-alone or 
adjuvant treatments for treating clinical conditions. Ginger (Zingiber officinale) has a 
long history in many cultures as a folk-remedy for nausea and gastrointestinal 
discomfort. Empirical research has demonstrated that ginger may be effective as an 
anti-nausea agent and in particular, it has been proposed as a possible candidate for 
anti-CINV therapy.  
While the exact mechanism of action is unknown, multiple active constituents within 
ginger (i.e. gingerols, shogoals, zingiberene, zingerone, and paradol) have been 
identified as potentially exerting beneficial effects on multiple areas implicated in the 
pathophysiology of CINV. Cell culture and animal studies suggest that these 
constituents stimulate oral and gastric secretions, regulate gastrointestinal 
motility,9,10 interact with the 5-HT3 receptors implicated in the CINV reflex,11  and 
assists in rescuing intracellular redox.12,13 Furthermore, animal studies provide 
preliminary support for the role of ginger supplementation in the prevention of 
cisplatin-induced emesis.14,15  
Few adverse effects from the ingestion of ginger are reported in the literature.16 Oral 
ginger is generally well tolerated, with mild gastrointestinal adverse effects including 
abdominal discomfort, heartburn, and diarrhoea being the most commonly reported. 
Theoretically, ginger inhibits platelet aggregation which could result in excessive 
bleeding, however this has not been reported in practice.17 When added to 
conventional anti-emetics used in the prophylaxis and treatment of CINV, ginger 
does not appear to increase adverse effects.18 Indeed, conventional anti-emetics 
appear to have a more varied adverse effect profile (including more severe adverse 
effects) compared to ginger. For example, steroids such as dexamethasone used for 
short durations commonly cause gastrointestinal adverse effects such as dyspepsia 
and psychological effects such as insomnia, while 5-HT3 receptor antagonists such 
as ondansetron commonly cause constipation and headache.19,20  
Whilst direct cost comparison between ginger and standard anti-emetic therapies is 
difficult due to lack of dose equivalency, it is likely that ginger would compare well, 
given its low ingredient cost and accessibility. Ginger is already readily available in 
several commercial non-prescription formulations, and requires little technical 
innovation in terms of cultivation and preparation.21 
Ernst et al.16 published a review on the effect of ginger on nausea and vomiting in a 
variety of settings, including only one paper that specifically investigated its effects 
on CINV. The review found that ginger was generally beneficial; however, firm 
conclusions could not be made due to the low number of studies in each setting. 
Multiple papers have since been published in this area and therefore, our review 
aims to detail the current published research from randomised, controlled trials 
(RCTs) and evaluate the efficacy of ginger in the prevention of CINV, highlighting 
areas for future investigation.  
Method 
A systematic search of the literature was conducted using PubMed, the Cochrane 
Library, and CINAHL, as well as bibliographies of past research on the subject (see 
Figure 1). Search terms were not limited by timeframe and therefore all searches 
were between April 2012 and the date of the databases inception. Articles were 
identified using the search terms “(“Zingiber officinale” OR “ginger”) AND (”cancer” or 
“chemotherapy”) AND (“nausea” OR “emesis” OR “vomit” OR “CINV”)”. Inclusion 
criteria for this review were: 1) RCT and/or cross-over trials that used either placebo 
or current anti-CINV treatment as a control; 2) In human participants, undergoing 
chemotherapy; 3) The use of ginger as the main intervention and specifically 
investigating its effects on nausea and vomiting; and 4) Published in English.  
All studies included in this review were analysed for common characteristics and 
methodologies, major findings, and potential limitations. Additionally, all studies were 
individually rated for evidence level using the National Health and Medical Research 
Council (NHMRC) Hierarchy of Evidence guidelines (IV-I, with I being the strongest 
level of evidence) as well as assessed in terms of quality (positive, neutral, negative) 
using the American Dietetic Association’s quality criteria checklist. 22,23  
The overall body of evidence (based on a summary of the individual studies) 
evaluated within this review was assessed using a separate tool, the NHMRC’s body 
of clinical evidence assessment matrix, an assessment tool that assigns a letter 
grade (A: strongest to D: weakest) based on the strength of the literature included in 
a review. 22 
Results 
The search strategy identified seven studies (Table 1) that provided Level II 
evidence and all had a positive quality rating. Hence, all studies included in this 
review possessed attributes consistent with rigorous scientific method, such as 
randomised group allocation and clear inclusion and/or exclusion criteria. Of note, 
two studies did not meet the inclusion criteria as they were unpublished literature 
(Pecoraro et al.24, Pace et al.25) and two studies (Levine et al.26, Meyer at al.27) were 
excluded as they utilised an ineligible study design.  
Study characteristics  
All seven studies included in this review were RCTs, three of which were cross-over 
trials. Two cross-over trials used current anti-CINV treatment as the control group 
rather than placebo.28,29 Five of the seven studies had relatively small sample sizes 
(approximately 30-70 participants in total). Zick et al.18 and Ryan et al.30 were the 
exceptions, with 129 and 576 participants completing each trial respectively. The 
length and timeframe of symptom assessment varied between studies, with 
assessment of CINV symptoms conducted anytime from three days prior to 
chemotherapy treatment and up to 10 days post-treatment. The outcomes measured 
in the majority of studies (5/7) were acute nausea and vomiting (24 hours post-
chemotherapy) and delayed nausea and vomiting (between two and ten days post-
chemotherapy); however, Ryan et al.30 did not measure vomiting symptoms and 
Sontakke et al.28 measured acute nausea and emetic events only.  
Typical dosing regimens were 1g to 2g of ginger, divided into four to eight capsules 
and consumed over a period of one to ten days. The majority of studies used 
powdered ginger preparations, while two studies used extracts that were 
standardised to either their gingerol content or to a combination of active compounds 
(shogoals, gingerols and zingerone). Zick et al.18 independently verified the 
preparations using high-performance liquid chromatography to ensure the potency of 
the intervention and found their extract contained “5.38 mg (2.15%) 6-gingerol, 1.80 
mg (0.72%) 8-gingerol, 4.19 mg (1.78%) 10-gingerol, and 0.92 mg (0.37%) 6-
shogaol”. Ryan et al.30 reported that the ginger preparation used within their study 
contained 8.5mg of active constituents per capsule; however, it was unclear whether 
this was independently analysed or from the manufacturers’ analysis. None of the 
studies that used a powdered formulation reported an analysis of active constituents. 
The timing of doses did not vary greatly between studies, with the initial dose 
generally given +/-1 hour of the first chemotherapy session. Ryan et al.30 was the 
exception to this in providing ginger supplementation for the three days prior to 
chemotherapy. 
Five of the seven studies used standard anti-CINV medication in conjunction with 
ginger. In the two studies that did not use ginger as an adjuvant to standard therapy, 
ginger was compared to ondansetron and metoclopramide as a stand-alone 
treatment in a cross-over trial28 or combined with standard anti-CINV treatment in the 
acute phase, but compared as a stand-alone treatment in the delayed phase of the 
study.29 Participants in four of the seven of studies were adults of mixed gender, with 
the exceptions of Panahi et al.31 and Manusirivithaya et al.29 who studied females 
and Pillai et al.32 who studied children.  
Study results 
The results of the included studies were mixed. Two of the seven studies reported no 
benefit,18,33 three determined some benefit on measures of CINV (measures of either 
acute nausea30,31 or both acute and delayed nausea and vomiting32) and two 
reported that ginger performed equally as well as metoclopramide (Table 2).28,29 Zick 
et al.18 found that  higher doses (2g) of ginger had a negative effect on delayed-CINV 
in participants prescribed aprepitant (p=0.01).16  
Sontakke et al.28 found 2g of ginger effective in reducing acute CINV equal to 
metoclopramide; Pillai et al.32 determined that 1-2g of ginger was effective in 
reducing the severity of both acute and delayed CINV by 37-47%; while Ryan et al.30 
reported that all doses used in the intervention successfully reduced symptoms of 
acute nausea by 0.16-0.44 on a 1-7 Likert scale in patients experiencing mild 
baseline-CINV (p=0.003), with 0.5g and 1g (p=0.017 and p=0.036, respectively) 
being the most effective doses;, however, delayed nausea and quality of life were 
not affected by ginger supplementation. A 16% reduction in acute nausea during the 
first 6-24 hours post-chemotherapy was also found by Panahi et al.31 using 1.5g of 
ginger (p=0,04).    
Manusirivithaya et al.29 reported that during the acute phase of chemotherapy, 1g of 
ginger did not further reduce CINV when combined with metoclopramide therapy. It 
did, however, perform equally to metoclopramide during the delayed phase (2-5 days 
post-chemotherapy). Zick et al.18 and Fahimi et al.33 found no additional benefit when 
ginger was used as an adjuvant therapy to standard nausea and emetic control.  
A variety of tools were used to assess nausea and vomiting in the studies reviewed. 
Two studies measured symptoms using a modified version of the Morrow 
Assessment of Nausea and Emesis (MANE),18,33 a validated instrument for 
assessing nausea in cancer patients34; Pillai et al.32 employed the Edmonton 
Symptom Assessment Scale and the National Cancer Institute Guidelines for 
Nausea and Vomiting, respectively; two studies used an unspecified tool28,29;  
Panahi et al. 31 employed the Rhodes Index of Nausea, Vomiting, and Retching; and 
Ryan et al.30 utilized a tool developed by Burish and Carey.35  
Five of the seven studies specifically included patients receiving highly emetogenic 
chemotherapy regimens; however, while all being highly emetogenic regimens, there 
was little consistency in the agent and protocol used. The remaining two studies 
included patients undergoing combination chemotherapy containing agents with 
different degrees of emetogenicity.18,30 
Adverse events and adherence 
Despite previous research indicating that ginger supplementation could theoretically 
cause excessive bleeding in susceptible patients due to the inhibition of platelet 
aggregation,36 all adverse events that were attributed to the intervention were non-
serious in nature. The most common reactions reported included heartburn, bruising 
or flushing, rash, and gastrointestinal discomfort. Adverse events were generally not 
significantly higher in the ginger group compared to the control group in any study. 
Most studies (5/7) reported some degree of non-adherence during their 
investigations. Studies that included information regarding adherence found a rate 
between 75-90%.18,30,31,33 The exact method for determining adherence was not 
stated in five of the seven studies, however, Ryan et al.30 reported that adherence 
was measured by counting the amount of remaining pills at the end of each study 
cycle while Panahi et al.31 measured self-reported adherence.  
Discussion 
The evidence is mixed in its support of ginger as an adjuvant or stand-alone 
treatment for CINV. Of the seven RCTs published to date; five reported favourable 
results while two were unfavourable. Of the five favourable studies, three studies 
reported ginger as improving some measure of CINV when combined with standard 
anti-CINV treatment, with Ryan et al.30 and Panahi et al.31 reporting a reduction in 
acute nausea and Pillai et al.32 reporting a reduction in acute and delayed nausea 
and vomiting. The two other favourable studies found ginger reduced some measure 
of CINV equal to metoclopramide but due to the lack of a placebo group in both 
studies, it is difficult to determine the clinical significance of these results28,29. This is 
due to the fact that in both of these trials, the percentage of individuals that reported 
symptoms in the ginger group was still within the predicted emetic risk for the 
chemotherapy regimen used and therefore, without a placebo group, it is difficult to 
determine the intervention’s true impact. Results from positive trials have found 
ginger to reduce measures of CINV by 16-47% and while these findings need to be 
reconciled with the negative findings from other studies in this review, this magnitude 
of reduction could provide meaningful relief to patients experiencing CINV. 
Using the NHMRC body of evidence assessment matrix, our review indicates that 
there is C level evidence for the use of ginger as an anti-nausea agent in this 
context. Therefore while there is some supporting evidence for its use, the 
considerable inconsistency in study methods and outcomes reported here reflect 
genuine uncertainty about its use in the chemotherapy setting. Until this uncertainty 
is resolved, professional opinion will continue to guide the healthcare team when 
choosing ginger as a treatment option.  
Confounding factors within current literature  
There are multiple factors that explain the mixed results reported in the literature. 
One possible explanation is that some ginger preparations have higher levels of 
certain active compounds when compared to the preparations used in other studies. 
Research investigating the concentration of active compounds in commercial ginger 
products indicates that the levels of these compounds can vary greatly between 
products, demonstrating a need to analyse ginger interventions for their active 
compounds and to utilise standardised extracts rather than powdered 
formulations.37,38 In order to improve the significance of future trials in this area, 
dose-finding studies using varied standardised extracts are required to determine the 
effective dose and preparation of ginger. 
Recent studies have also determined that once a patient undergoing chemotherapy 
develops any form of nausea or vomiting (i.e. anticipatory, acute, delayed), 
regardless of the emetogenicity of that treatment, the likelihood of that patient 
experiencing nausea for the remainder of their treatment regimen is significantly 
higher and more difficult to treat with standard anti-CINV medication. 39 This is due to 
the complex aetiology of CINV, a response that is initiated by varying stimuli within 
the central and peripheral nervous systems. These include the effects of 
chemotherapy on both the central nervous system and gastrointestinal tract as well 
as the effect of sensory input (e.g. smell, sight) and the psychological conditions of 
the individual (e.g. fear, anxiety).40 These stimuli activate peripheral and central 
nerve signals which are then received by the chemoreceptor trigger zone an area 
within the brain, which coordinates the body’s emetic response base. Anticipatory 
nausea and vomiting is thought to be a conditioned response to previous 
chemotherapy exposure. Anticipatory CINV  is mediated by the central nervous 
system and is caused by the coupling of neutral stimuli (such as the smell or sight of 
the hospital environment) with the undesirable effects of chemotherapy, which then 
results in the initially neutral stimuli eliciting a similar response to the cytotoxic 
treatment.41  Since many studies in this review included patients who had previously 
experienced CINV, the participants within these studies might have had an increased 
resistance to the intervention due to conditioning. This is of particular concern in the 
studies that used a cross-over design, as patients who were initially in the control 
group could have had established resistance to the intervention when subsequently 
crossed-over. Conducting statistical analysis to ensure that the sequence of 
intervention does not influence the results, as undertaken by Manusirivithaya et al.29 
and Zick et al.18, will help monitor this effect. Alternatively, Roscoe and 
colleagues30,42 were able to determine that a self-assessed susceptibility to nausea 
and vomiting by chemotherapy patients was a predictor of CINV and might be a 
viable method of screening in future trials.  
Research has found that female patients are significantly more likely to experience 
CINV than their male counterparts.43  The majority of studies (5/7) included a sample 
that was predominantly female, of which four studies reported benefits from ginger 
treatment. This suggests that gender may have influenced the patients’ response to 
ginger treatment, possibly by decreasing the threshold at which CINV is experienced 
and thereby increasing the efficacy of anti-CINV treatments. In light of this, the null 
results reported by Fahimi et al.33 may be partially explained by the male-dominant 
sample. In this study, the severity of nausea in both the intervention and control 
group was rated as low at all time points which indicates that the patients within this 
study may not have been experiencing CINV at a sufficiently high level of severity to 
have responded to anti-CINV intervention. This may also explain the results found by 
Pillai et al.32 When the gender distributions between the control and treatment group 
were compared, there was a greater proportion of men within the experimental group 
compared to the control, which almost reached statistical significance (p=0.055). 
This may have also resulted in the experimental group being more resistant to CINV 
compared to the control group regardless of ginger treatment. Therefore, similarly to 
anticipatory nausea, future trials should either include screening protocols or conduct 
statistical analyses to account for gender variations within the study sample.   
Additionally, because of the subjective nature of nausea, direct comparison of 
findings can be difficult and therefore investigators should aim to use validated tools 
such as the MANE, which would ensure that results are both validated and easily 
comparable to other studies. It should be noted that the two studies that failed to find 
any benefit from ginger supplementation both used the MANE as the assessment 
tool, which suggests that the use of different assessment tools used within each 
Formatted: Superscript
study might have been a factor contributing to the mixed results of the reviewed 
literature.18,33  
Another concern is that due to the distinctive aroma of ginger, it is important to 
ensure that studies are properly blinded. For example, Zick et al.18 tested the 
effectiveness of the blinding in their investigation. While they had taken steps to 
ensure adequate blinding, the participants were able to discern the intervention 
group from the placebo at a statistically significant rate (p=0.01). To overcome this 
problem, Ryan et al.30 utilised a combination of double encapsulation with a nitrogen 
cap to mask the odour and colour of the ginger. While this is an example of a 
potentially effective blinding technique, they did not test its effectiveness. 
Interestingly, Ryan et al’s.30 was one of the two studies that reported positive results 
when ginger was used as an adjuvant therapy; effective blinding may, at least in 
part, help explain the disparity of results between studies within this review. Future 
clinical trials should incorporate more stringent blinding procedures to avoid a 
potential placebo or nocebo effect from occurring.  
Possible drug-interactions at high doses 
An interesting result reported within two studies in this review is that when subjects 
were given higher doses (1.5-2g) of ginger, there was a statistically significant 
decline in CINV control when compared to the participants that either received lower 
doses or the placebo. Zick et al.18 reported that when subjects received a 
combination of 2g ginger plus aprepitant (an NK1 inhibitor), the severity of delayed 
nausea increased when compared to control (p=0.01). Similarly, Ryan et al.30 
concluded that while all doses of ginger were effective in reducing acute CINV, 1.5g 
of ginger was less effective when compared to the 0.5g and 1g of ginger 
preparations. These findings corroborate previous studies in this field, which 
reported that higher doses of ginger were less effective when treating nausea from 
causes other than chemotherapy.44,45 This led Zick et al.18 to hypothesise that ginger 
reduces absorption of medication by increasing gastric emptying and intestinal 
motility, which has been demonstrated in animal models. However, research in 
human trials has not determined that ginger affects gastric emptying rates.46,47 
Another hypothesis is that ginger competitively interacts with the same receptors that 
standard anti-CINV medication acts upon; thereby reducing the binding rate of 
medications when used in combination.30  Animal studies support this hypothesis, 
indicating that gingerols and shoagoals are able to bind to both 5-HT3 and substance 
P receptors, which are the receptors that medications such as aprepitant and 
ondansetron interact with.48,49 It should also be noted that these studies showed that 
different ginger compounds bound to these receptors with varying strengths and 
therefore, different preparations of ginger could exert differing effects on nausea. 
This highlights further limitations in our current understanding in this area, as there 
are multiple active compounds in ginger that appear to be responsible for these 
interactions. This poses a significant limitation to the current research as the majority 
of studies, excluding Zick et al.18 and Ryan et al.30, used ginger preparations with 
unknown levels of these active constituents.  
Clinical Implications 
The feasibility of ginger supplementation has not been extensively or rigorously 
studied in chemotherapy populations. Fatigue, mouth sores and taste sensitivities 
are all common symptoms that chemotherapy patients experience while undergoing 
treatment. Given that some studies included in this review have used up to 8 
capsules, consumed at multiple times throughout the day, this could place a 
significant burden on a population group who might already be compromised. Future 
research is required to investigate areas of practice such as participant tolerability 
and adherence to the intervention, in addition to its effect on quality of life and patient 
satisfaction with the intervention, in order to determine its real-world efficacy.   
Review limitations 
The exclusion of unpublished literature may have affected this review by introducing 
a publication bias; however, the two unpublished studies that were identified and 
excluded from this review both reported positive results and therefore this seems 
unlikely.24,25   
Conclusion 
Despite the widespread use of ginger in the treatment of nausea in other contexts 
such as gestational nausea, the current literature provides mixed support for the use 
of ginger as a standard part of anti-CINV control for patients undergoing 
chemotherapy. Hence standard recommendations for such use are premature. This 
review has discussed some of the limitations in our current understanding of the area 
and highlights the need for further investigation. In particular, issues regarding 
rigorous blinding procedures, patient screening, timing of the intervention to 
encompass the range of CINV, and ginger preparation should be considered in 
future research in this area. Our analysis of the evidence using NHMRC grading 
indicates that ginger may be useful for some patients but also that care needs to be 
taken in its application until further studies are conducted.  
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Figure 1. Flow of information for systematic review. 141 
Table 1. Studies reviewed  
Author 
 
Study Design Population Type of cancer Chemotherapy 
Protocol 
Country Level of 
evidence 
Quality 
Ryan et al. 
(2012)30 
 
Randomized, 
double-blind, 
placebo-
controlled, 
dose-finding 
trial 
576 adult cancer 
patients. Mean 
age of 53 years. 
93% women. 
72% Breast, 
28% 
Alimentary 
Genitourinary, 
Gynaecologic, 
Hematologic, 
Lung. 
Not specified. USA II Positive 
Panahi et al. 
(2012)31 
 
Randomized, 
open-label, 
pilot clinical 
trial 
78 women. Mean 
age: 51.83 years.  
Advanced 
breast cancer 
Predominately, the TEC 
regimen (docetaxel, 
epirubicin, and 
Cyclophosphamide).  
Iran II Positive 
Pillai et al. 
(2011)32 
 
Prospective, 
double-blind, 
randomized 
controlled trial 
58 children, 
cancer patients. 
Mean age: 15 
years. 40 men, 
Bone sarcoma. Combination of cisplatin 
(40 mg/m2/day) and 
doxorubicin (25 
mg/m2/day). 
India II Positive 
20 women.  
Fahimi et al. 
(2010)33 
 
Randomized, 
cross-over, 
double-blinded, 
placebo-
controlled trial 
36 adult cancer 
patients. Mean 
age of 50.23 
years. 10 
women, 26 men. 
50% Lung 
cancer, 50% 
Unspecified. 
Cisplatin with at least 
one of the following 
agents: Etoposide, 
Docetaxel, Gemcitabine, 
Docetaxel, Vinorelbine 
Cyclophosphamide, 
Paclitaxel, Doxorubicin, 
5-FU, Pemetrexed. 
Iran II Positive 
Zick et al. 
(2009)18 
 
Randomized, 
double-blind, 
placebo-
controlled trial 
129 adult cancer 
patients. Mean 
age of 55.5-58 
years. 
Approximately 
75% female. 
Unspecified. Multiple regimens of 
varying emetogenicity. 
USA II Positive 
Manusirivithaya 
et al. (2004)29 
Randomized, 
double-blind 
43 female cancer 
patients. Mean 
76% Ovary, 
23% Cervix. 
Cisplatin with one of the 
following agents: 
Thailand II Positive 
 crossover trial age of 43 years. cyclophosphamide, 
ifosfamide, etoposide & 
bleomycin, 5-
fluorouracil. 
Sontakke et al. 
(2003)28 
 
Randomized, 
prospective, 
cross-over, 
double-blind 
trial 
50 cancer 
patients. Median 
age of 46 years. 
39 female, 11 
male. 
Unspecified. Cyclophosphamide 
(500-1000mg) with at 
least one of the 
following agents: 
vincristine, 
methotrexate, 5-
fluorouracil, actinomycin 
D. 
India II Positive 
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Table 2. Study results 
Author 
 
Ginger 
regimen 
Duration of 
intervention 
Endpoint 
measured Results and adherence Comments 
Ryan et al. 
(2012)30 
 
Placebo, 0.5g 
ginger, 1g 
ginger or 1.5g 
ginger (6 
capsules, 
combination of 
ginger and 
placebo). 
Received 
regimen for 2 X 6 
day periods. 
Measured for 3 X 
4 day periods. 
Primary objective: 
acute nausea. 
Secondary 
objectives: 
delayed nausea, 
anticipatory 
nausea, 
and quality of life. 
All doses reduced acute 
nausea (p=0.003) but not 
delayed, using an assessment 
tool developed by Burish and 
Carey.35  
77.4% of participants 
completed the trial 
(n=576/744), 83-93% 
adherence rate depending on 
treatment arm. 
0.5 and 1g doses were most 
effective in reducing acute 
CINV. Largest study to date. 
Panahi et al. 
(2012)31 
 
1.5g (3 X 
500mg) 
4 days post-
chemotherapy 
Prevalence, 
score, and 
severity of 
nausea, vomiting, 
and retching 
Reduction in nausea 6 to 24 
hours post-chemotherapy (p = 
0.04) using a simplified version 
of the Rhodes Index of 
Nausea, Vomiting, and 
Non-blinded. Sample group 
relatively homogenous 
compared to other studies in 
this review.  
Retching. All other measures 
were non-significant. 
78% of participants completed 
the trial (n=78/100), 18 
participants were withdrawn 
due to lack of adherence or 
were lost to follow-up. 
 
Pillai et al. 
(2011)32 
 
1g ginger (6 X 
167mg) or 2g 
(5 X 400mg) 
determined by 
participants 
weight, or 
placebo. 
Received 
regimen for 3 
days post-
chemotherapy, 
measured 
symptoms for 10 
days post-
chemotherapy. 
Incidence and 
severity of acute 
and delayed 
nausea and 
emetic events.  
Reduction in moderate and 
severe acute nausea and 
emesis (p=0.003, p=0.002, 
respectively) and reduction in 
moderate and severe delayed 
nausea and emesis (p<0.001, 
p=0.022, respectively), using 
Edmonton’s Symptom 
Assessment Scale and 
National Cancer Institute 
Experimental group 
contained a larger 
proportion of males, almost 
reaching statistical 
significance. Gender may 
influence susceptibility to 
nausea and vomiting. 
guidelines.  
95% of participants completed 
the trial (n=57/60), 2 
participants were withdrawn 
due to non-adherence with 
data collection protocol.   
Fahimi et al. 
(2010)33 
 
1g (4 X 
250mg) or 
placebo then 
crossed over. 
2 X 3 day periods 
with a 3 week 
washout period in 
between. 
Prevalence, 
severity and 
duration of acute 
and delayed 
nausea and 
emetic events.  
No benefit in any measure of 
acute or delayed CINV, using 
MANE assessment tool. 
Prevalence: Day 1 (p=0.14). 
Day 2 (p=0.31). Day 3 
(p=0.73). 
72% of participants completed 
the trial (n=36/50), 13 
participants were withdrawn 
due to non-adherence. 
  
Zick et al. 
(2009)18 
 
1g (4 X 
250mg, 4x 
placebo) or 2g 
(8 X 250mg) 
per day or 
placebo. 
3 days post-
chemotherapy 
Primary objective: 
Severity and 
prevalence of 
delayed nausea 
and emetic 
events. 
Secondary 
objectives: 
Severity and 
prevalence of 
acute nausea and 
emetic events as 
well determine 
safety and 
blinding of study. 
No benefit in any measure of 
acute or delayed CINV, using 
MANE assessment tool. 
Prevalence:  Acute: p=0.86 
Delayed: 0.16 Severity: Non-
Appretiant group: Acute: 
p=0.47, Delayed: p=0.69. 
80% of participants completed 
the trial (n=129/162). Authors 
reported 79% of participants 
reported consuming 80% of all 
study medication. 
Delayed nausea was more 
severe in participants 
receiving 2g ginger with 
aprepitant. Blinding 
assessment found that 
participants were more likely 
to correctly determine which 
treatment group they were 
assigned to. 
Manusirivithaya 
et al. (2004)29 
 
1g ginger (4 X 
250mg) or 
placebo then 
2 X 5 day periods 
with 3-4 week 
washout period 
Acute and 
delayed nausea 
and emetic 
No benefit in acute nausea. 
Reduction in delayed CINV 
equal to standard treatment. 
The name of assessment 
tool in this study was not 
identified.   
crossed over. in-between events.  90% of participants completed 
the trial (n=43/48). No data on 
adherence rate specified. 
In delayed phase, ginger 
was compared as a stand-
alone treatment to 
metoclopramide, not 
placebo.  
Sontakke et al. 
(2003)28 
 
2g (4 X 
500mg) ginger, 
crossed over 
with two 
control groups 
3 X 24 hour 
periods with 21 
days between 
sessions 
Control of acute 
nausea and 
emesis. 
Complete control of vomiting 
was achieved in 68% of 
patients with ginger, 64% with 
metoclopramide and 86% with 
ondansetron 
Complete control of nausea 
was achieved in 62% of 
patients with ginger, 58% with 
metoclopramide and 86% with 
ondansetron. No data on 
withdrawals or adherence was 
specified. 
Compared ginger to 
standard emetics as a 
standalone therapy.  
The name of assessment 
tool in this study was not 
identified.   
Abbreviations: MANE, Morrow Assessment of Nausea and Emesis; CINV, Chemotherapy-induced Nausea and Vomiting. 147 
